LT3265448T - Riluzolo provaistai ir jų naudojimas - Google Patents

Riluzolo provaistai ir jų naudojimas

Info

Publication number
LT3265448T
LT3265448T LTEPPCT/US2016/019787T LT16019787T LT3265448T LT 3265448 T LT3265448 T LT 3265448T LT 16019787 T LT16019787 T LT 16019787T LT 3265448 T LT3265448 T LT 3265448T
Authority
LT
Lithuania
Prior art keywords
riluzole prodrugs
riluzole
prodrugs
Prior art date
Application number
LTEPPCT/US2016/019787T
Other languages
English (en)
Inventor
Jay Edward Wrobel
Allen B. Reitz
Jeffery Claude Pelletier
Garry Robert Smith
Haiyan Bian
Original Assignee
Biohaven Pharmaceutical Holding Company Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Company Ltd. filed Critical Biohaven Pharmaceutical Holding Company Ltd.
Publication of LT3265448T publication Critical patent/LT3265448T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LTEPPCT/US2016/019787T 2015-03-03 2016-02-26 Riluzolo provaistai ir jų naudojimas LT3265448T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127684P 2015-03-03 2015-03-03
PCT/US2016/019787 WO2016140879A1 (en) 2015-03-03 2016-02-26 Riluzole prodrugs and their use

Publications (1)

Publication Number Publication Date
LT3265448T true LT3265448T (lt) 2022-04-11

Family

ID=56848452

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/019787T LT3265448T (lt) 2015-03-03 2016-02-26 Riluzolo provaistai ir jų naudojimas

Country Status (25)

Country Link
US (9) US10639298B2 (lt)
EP (2) EP4011870A1 (lt)
JP (2) JP6700293B2 (lt)
KR (2) KR102587894B1 (lt)
CN (1) CN107567438B (lt)
AU (3) AU2016226463B2 (lt)
BR (1) BR112017018832B1 (lt)
CA (1) CA2978158C (lt)
CY (1) CY1125112T1 (lt)
DK (1) DK3265448T3 (lt)
EA (1) EA034759B1 (lt)
ES (1) ES2905318T3 (lt)
HK (1) HK1248706A1 (lt)
HR (1) HRP20220208T1 (lt)
HU (1) HUE058204T2 (lt)
IL (2) IL253989B (lt)
LT (1) LT3265448T (lt)
MX (1) MX2017011196A (lt)
PH (1) PH12017501576A1 (lt)
PL (1) PL3265448T3 (lt)
PT (1) PT3265448T (lt)
RS (1) RS62915B1 (lt)
SG (2) SG10201908354VA (lt)
SI (1) SI3265448T1 (lt)
WO (2) WO2016140878A2 (lt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
SI3220891T1 (sl) * 2014-11-21 2020-02-28 Biohaven Therapeutics Ltd. Podjezična formulacija riluzola
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
CN107567438B (zh) * 2015-03-03 2021-06-29 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
US20210228549A1 (en) * 2015-03-03 2021-07-29 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
JP2017061430A (ja) * 2015-09-25 2017-03-30 芳男 ▲浜▼田 新規なプロドラッグ
ES2912131T3 (es) 2016-05-20 2022-05-24 Biohaven Therapeutics Ltd Uso de agentes moduladores del glutamato con inmunoterapias para tratar el cáncer
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
US20210212999A1 (en) * 2017-01-18 2021-07-15 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
US20180207138A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
WO2018157820A1 (zh) * 2017-02-28 2018-09-07 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物
CN107021959A (zh) * 2017-05-02 2017-08-08 青岛科技大学 一类新型吲哚衍生物及其体外抗肿瘤活性
MX2020004678A (es) * 2017-11-12 2020-08-13 Biohaven Pharm Holding Co Ltd Uso de profarmacos de riluzol para tratar ataxias.
SG11202100385YA (en) * 2018-07-22 2021-02-25 Biohaven Therapeutics Ltd Use of riluzole prodrugs to treat alzheimer's disease
CA3109769A1 (en) * 2018-08-16 2020-02-20 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases
GB201818651D0 (en) * 2018-11-15 2019-01-02 Univ Sheffield Compounds
IL291891A (en) * 2019-10-10 2022-06-01 Biohaven Therapeutics Ltd Prodrug of myeloperoxidase inhibitors
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
WO2021262914A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US20240082340A1 (en) * 2021-01-18 2024-03-14 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
EP4294392A1 (en) * 2021-02-22 2023-12-27 Yale University, Inc. Targeted bifunctional degraders and methods using same
KR20240025777A (ko) 2022-08-19 2024-02-27 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用
WO2024006678A1 (en) * 2022-06-26 2024-01-04 Biohaven Therapeutics Ltd. Methods of treating glioblastoma with prodrugs of riluzole
CN118085016B (zh) * 2024-04-24 2024-07-30 天津卡普希科技有限公司 一种d-苯甘氨酰-甘氨酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291015T1 (de) * 1997-11-05 2005-04-15 Mitsubishi Chem Corp Alkylaminoderivate
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
KR100842135B1 (ko) * 2004-07-21 2008-06-27 미쓰이 가가쿠 가부시키가이샤 디아민 유도체, 그 제조 방법 및 그것들을 유효 성분으로 하는 살균제
EP1874353A1 (en) 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US10357497B2 (en) 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
CN107567438B (zh) * 2015-03-03 2021-06-29 拜尔哈文制药股份有限公司 利鲁唑前药及其用途
US20210228549A1 (en) * 2015-03-03 2021-07-29 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ES2969792T3 (es) 2015-11-19 2024-05-22 Biohaven Therapeutics Ltd Profármacos de amina de compuestos farmacéuticos
ES2912131T3 (es) * 2016-05-20 2022-05-24 Biohaven Therapeutics Ltd Uso de agentes moduladores del glutamato con inmunoterapias para tratar el cáncer
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
MX2020004678A (es) 2017-11-12 2020-08-13 Biohaven Pharm Holding Co Ltd Uso de profarmacos de riluzol para tratar ataxias.

Also Published As

Publication number Publication date
HUE058204T2 (hu) 2022-07-28
IL278080A (en) 2020-11-30
US12005046B2 (en) 2024-06-11
AU2022202163B2 (en) 2024-02-29
MX2017011196A (es) 2018-05-22
BR112017018832B1 (pt) 2023-12-26
WO2016140878A9 (en) 2016-10-20
EA201791951A1 (ru) 2018-01-31
US20200085794A1 (en) 2020-03-19
US10905681B2 (en) 2021-02-02
CN107567438B (zh) 2021-06-29
DK3265448T3 (da) 2022-03-28
WO2016140879A9 (en) 2016-11-03
US12005047B2 (en) 2024-06-11
US10639298B2 (en) 2020-05-05
US20180036290A1 (en) 2018-02-08
JP2020128401A (ja) 2020-08-27
KR20230147746A (ko) 2023-10-23
US20230017637A1 (en) 2023-01-19
WO2016140879A1 (en) 2016-09-09
KR20180008402A (ko) 2018-01-24
SG10201908354VA (en) 2019-10-30
JP7012117B2 (ja) 2022-02-10
WO2016140878A2 (en) 2016-09-09
PL3265448T3 (pl) 2022-04-25
US20200289475A1 (en) 2020-09-17
JP6700293B2 (ja) 2020-05-27
EP4011870A1 (en) 2022-06-15
SI3265448T1 (sl) 2022-04-29
PH12017501576B1 (en) 2018-03-12
IL278080B (en) 2022-03-01
PT3265448T (pt) 2022-02-04
CA2978158C (en) 2022-04-12
RS62915B1 (sr) 2022-03-31
ES2905318T3 (es) 2022-04-07
EP3265448A4 (en) 2018-11-07
AU2016226463B2 (en) 2020-06-25
US10485791B2 (en) 2019-11-26
PH12017501576A1 (en) 2018-03-12
BR112017018832A2 (pt) 2018-04-24
WO2016140878A3 (en) 2016-11-24
EP3265448A1 (en) 2018-01-10
US20240091205A1 (en) 2024-03-21
AU2020233650B2 (en) 2022-04-07
AU2016226463A1 (en) 2017-09-21
HRP20220208T1 (hr) 2022-04-29
IL253989A0 (en) 2017-10-31
IL253989B (en) 2020-11-30
CN107567438A (zh) 2018-01-09
HK1248706A1 (zh) 2018-10-19
US20180037557A1 (en) 2018-02-08
EA034759B1 (ru) 2020-03-17
JP2018508525A (ja) 2018-03-29
AU2022202163A1 (en) 2022-04-21
US20210236471A1 (en) 2021-08-05
KR102587894B1 (ko) 2023-10-12
SG11201706831RA (en) 2017-09-28
CA2978158A1 (en) 2016-09-09
US20230381149A1 (en) 2023-11-30
CY1125112T1 (el) 2024-02-16
AU2020233650A1 (en) 2020-10-08
US11052070B2 (en) 2021-07-06
US20230381150A1 (en) 2023-11-30
EP3265448B1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
IL278080B (en) Riluzole prodrugs and their use
IL264258B (en) Diazahetero-bicyclic substituted compounds and their use
IL264813B (en) 2-oxo-imidazopyridines and their use
HK1247576A1 (zh) 氧雜二環庚烷前藥
IL268048A (en) Preparation salts and compounds of 1-methyl-d-tryptophan
HK1256902A1 (zh) 氯犬尿氨酸的前體藥物
GB201504763D0 (en) Compounds and uses
HK1243077A1 (zh) 呱啶基吡唑並嘧啶酮及其用途
GB201522309D0 (en) Use
GB201522311D0 (en) Use
GB201521085D0 (en) Use
GB201515194D0 (en) Nappy and insert therefor
GB201518466D0 (en) Use
GB201510077D0 (en) Use
IL258458B (en) Peroxyhemiacetal profragrant and proflavor compounds
GB2543375B (en) Compounds and their uses
GB2545167B (en) Cloches and use thereof
GB201514770D0 (en) Compounds and their use
GB201522690D0 (en) Nanostructured surfaces
GB201513318D0 (en) Novel compounds and their use
GB201522411D0 (en) Use
GB201522443D0 (en) Use
GB201518142D0 (en) Concept ABCD3
AU2015132V (en) CHACER01 Acer palmatum
GB201515987D0 (en) Use